Muhlenkamp & CO Inc Affimed N.V. Transaction History

Muhlenkamp & CO Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 11, 2018	SELL	$1.25 - $2.65 $76,250 - $161,650	-61,000 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$1.23 - $2.3 $1,888 - $3,530	-1,535 Reduced 2.45%	61,000 $79,000
Q3 2017 Nov 13, 2017	SELL	$1.95 - $2.25 $19,989 - $23,064	-10,251 Reduced 14.08%	62,535 $141,000
Q2 2017 Aug 11, 2017	BUY	N/A	72,786	72,786 $149,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $5.97M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Muhlenkamp & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Muhlenkamp & CO Inc with notifications on news.